GSA Capital Partners LLP Increases Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

GSA Capital Partners LLP grew its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 441.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 8,682 shares of the company’s stock after buying an additional 7,078 shares during the quarter. GSA Capital Partners LLP’s holdings in Neurocrine Biosciences were worth $1,000,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Ashton Thomas Private Wealth LLC purchased a new stake in Neurocrine Biosciences in the second quarter worth $28,000. Innealta Capital LLC purchased a new stake in Neurocrine Biosciences in the 2nd quarter valued at about $30,000. New Covenant Trust Company N.A. bought a new position in Neurocrine Biosciences in the 1st quarter worth about $32,000. EdgeRock Capital LLC purchased a new position in shares of Neurocrine Biosciences during the second quarter worth approximately $35,000. Finally, Plato Investment Management Ltd bought a new stake in shares of Neurocrine Biosciences during the first quarter valued at approximately $41,000. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Price Performance

Shares of NBIX opened at $117.44 on Friday. The company’s fifty day moving average price is $118.56 and its 200-day moving average price is $132.81. Neurocrine Biosciences, Inc. has a 1-year low of $107.84 and a 1-year high of $157.98. The firm has a market capitalization of $11.89 billion, a PE ratio of 31.49 and a beta of 0.35.

Analyst Upgrades and Downgrades

NBIX has been the topic of several research reports. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a report on Monday, September 16th. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. HC Wainwright reissued a “buy” rating and set a $190.00 target price on shares of Neurocrine Biosciences in a research report on Friday, November 1st. JPMorgan Chase & Co. upped their price target on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Finally, BMO Capital Markets cut their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a report on Thursday, October 17th. Five investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $163.91.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.